Health
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients – News-Medical.Net
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at…
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude…
-
General21 hours agoAustralian racing driver James Wharton takes maiden Formula 3 race win
-
Noosa News15 hours agoFood supply chain system costs farmers and regions millions of dollars
-
Business15 hours agoBuy and hold NDQ and these ASX ETFs for 10 years
-
General17 hours ago“Accumulation of defects”. A-G report scathing on Navy shipbuilding